Kalaris Therapeutics, Inc. (KLRS) — 10-Q Filings

10-Q Filings (6)

• Kalaris Narrows Losses Post-Merger, Cash Position Strengthens — Nov 12, 2025 Risk: high
  Kalaris Therapeutics, Inc. (KLRS) reported a net loss of $11.894 million for the three months ended September 30, 2025, a significant improvement from the $38.0
• Kalaris' Losses Mount Post-AlloVir Merger, Cash Position Improves — Aug 13, 2025 Risk: high
  Kalaris Therapeutics, Inc. (KLRS) reported a net loss of $11.35 million for the three months ended June 30, 2025, an increase from $5.65 million in the prior-ye
• Kalaris Therapeutics Q1 2025 Revenue at $4.96M — May 14, 2025 Risk: medium
  Kalaris Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported $4.96 million in revenue for the first quarter of 2025. Key
• Allovir, Inc. Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  Allovir, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly ViraCyte, Inc., reported financial results and operational updates.
• Allovir, Inc. Files Q2 2024 10-Q — Aug 9, 2024 Risk: medium
  Allovir, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and operational highlights. Key financial data and
• Allovir, Inc. Files 10-Q for Period Ending March 31, 2024 — May 13, 2024 Risk: low
  Allovir, Inc. (KLRS) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Allovir, Inc. reported financial results for the quarter ended March 31, 2024

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX